Insights
Insights From Our Experts
Articles
Interpretation of the Europe Regulatory Framework and Best Practices for MI Across the Pharma Industry
Posted by
Michael DeLuca, PharmD, MBA, MSRA , Varun Pandey, PhD , Lindsey Buyskes, B Pharm , Natalia Gandarillas, MPharm on October 28, 202510/28/25
Navigating the European regulatory landscape for Medical Information (MI) is no easy feat. Recent research reveals that MI teams across pharma companies—large and small—face a patchwork of requirements and best practices, from consent handling and call…
How a Strategic Global HEOR Package Drives Market Access and Pricing Success
As ISPOR Europe 2025 approaches and momentum builds around how Health Economics and Outcomes Research (HEOR) continues to evolve—shaped by innovation, policy shifts and global collaboration, I’ve been reflecting on recent global product launches. What stands…
The Future of Personalized, Measurable MSL Engagement: Key Takeaways from Susan Giacalone
Not all data is equally valuable. Strategic medical insights—those that inform strategy and improve patient outcomes—are essential. In a recent article in Med Ad News (PharmaLive), Susan Giacalone explores how Medical Science Liaisons (MSLs) are redefining…
Let’s Be DIRECT: We Have An Access and Affordability Problem to Solve
Schedule a meeting to connect with one of our experts to explore whether a direct-to-patient or direct-to-provider model could be a good fit to your brand’s access and affordability strategy. The pharmaceutical industry is at an…
Seeing the Whole Picture: How Value & Evidence Generalists Drive Strategic Impact and Client Success
EVERSANA’s Powerful Matrix Approach to Value & Evidence EVERSANA’s Value & Evidence (V&E) team is comprised of seasoned HEOR researchers and industry experts who are collectively focused on improving healthcare outcomes and ultimately creating a healthier…
Identifying Challenges and Solutions for Indirect Comparisons in Myasthenia Gravis
Generalized myasthenia gravis (gMG) is a rare condition characterized by muscle weakness due to reduced connectivity between nerves and muscles throughout the body. There are many newer treatments for gMG, but no clinical trials directly comparing…
Navigating the New HTA Landscape: Pamela Vo on Strategic Evidence Planning
The implementation of the EU Health Technology Assessment (HTA) regulation marks a pivotal shift in how clinical evidence is evaluated across Europe. With the regulation now in effect, pharmaceutical companies face both new opportunities and new…
Disrupting the Life Sciences Commercial Model: EVERSANA Joins Insightful Conference Sessions on AI & Patient-Centric Models
Industry Thought Leaders Shape Wharton Conference On September 26, 2025, thought leaders from EVERSANA and across the healthcare, technology and life sciences industries gathered at The Wharton School in Philadelphia to participate in an exclusive scenario…
Brave New Commercialization World: Reimagining Global Launch Strategies in Life Sciences
The pace of change in global healthcare is accelerating and nowhere is this more evident than in the commercialization of new therapies and medical devices. Traditional launch strategies simply can’t keep up. Here at EVERSANA, we’re…
Strategic PICO Planning: Navigating Oncology Markets with NAVLIN by EVERSANA
Strategic PICO Planning in Oncology Markets In today’s dynamic healthcare environment, early and strategic PICO (Population, Intervention, Comparator, Outcome) planning is critical to successful evidence generation. With evolving regulatory frameworks—like the European Joint Clinical Assessment (JCA)—now…